Sutro Biopharma, Inc. – NASDAQ:STRO
Sutro Biopharma stock price today
$0.861
-1.02
-54.44%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Sutro Biopharma stock price monthly change
-54.57%
month
Sutro Biopharma stock price quarterly change
-54.57%
quarter
Sutro Biopharma stock price yearly change
-58.37%
year
Sutro Biopharma key metrics
Market Cap | 153.78M |
Enterprise value | 225.92M |
P/E | -1.92 |
EV/Sales | 2.22 |
EV/EBITDA | -1.35 |
Price/Sales | 2.18 |
Price/Book | 1.02 |
PEG ratio | 0.73 |
EPS | -1.89 |
Revenue | 154.06M |
EBITDA | -95.56M |
Income | -114.95M |
Revenue Q/Q | 2.63% |
Revenue Y/Y | 106.66% |
Profit margin | -181.13% |
Oper. margin | -184.2% |
Gross margin | 27.61% |
EBIT margin | -184.2% |
EBITDA margin | -62.03% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSutro Biopharma stock price history
Sutro Biopharma stock forecast
Sutro Biopharma financial statements
Average Price Target
$13
Potential upside: 1409.87%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10.41M | -38.52M | -370% |
|---|---|---|---|
| Sep 2023 | 16.92M | -49.28M | -291.21% |
| Dec 2023 | 113.72M | 31.06M | 27.32% |
| Mar 2024 | 13.00M | -58.21M | -447.52% |
| 2022-11-08 | -0.74 | -0.37 |
|---|---|---|
| 2023-03-30 | -0.74433 | -0.68 |
| Jun 2023 | 464899000 | 310.18M | 66.72% |
|---|---|---|---|
| Sep 2023 | 431734000 | 319.38M | 73.98% |
| Dec 2023 | 470736000 | 321.08M | 68.21% |
| Mar 2024 | 403402000 | 305.37M | 75.7% |
| Jun 2023 | -31.19M | 66.15M | 137.66M |
|---|---|---|---|
| Sep 2023 | -33.50M | -114.01M | -5.74M |
| Dec 2023 | 14.07M | -23.51M | -3.12M |
| Mar 2024 | -64.74M | 64.10M | -3.42M |
Sutro Biopharma alternative data
| Aug 2023 | 292 |
|---|---|
| Sep 2023 | 297 |
| Oct 2023 | 297 |
| Nov 2023 | 297 |
| Dec 2023 | 298 |
| Jan 2024 | 298 |
| Feb 2024 | 298 |
| Mar 2024 | 302 |
| Apr 2024 | 302 |
| May 2024 | 302 |
| Jun 2024 | 300 |
| Jul 2024 | 300 |
Sutro Biopharma other data
90.38%
+4.03%
of STRO is owned by hedge funds
112
-4
41.72M
+1.85M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 27041 |
| Jan 2024 | 0 | 12185 |
| Patent |
|---|
Application 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS Filling date: 17 Jun 2020 Issue date: 18 Aug 2022 |
Grant Filling date: 6 Apr 2020 Issue date: 9 Aug 2022 |
Grant Filling date: 7 Nov 2019 Issue date: 9 Aug 2022 |
Application Filling date: 10 Jun 2020 Issue date: 4 Aug 2022 |
Application Filling date: 28 Jul 2021 Issue date: 30 Jun 2022 |
Grant Utility: Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use Filling date: 15 Aug 2017 Issue date: 31 May 2022 |
Application ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES Filling date: 5 Aug 2021 Issue date: 7 Apr 2022 |
Application Filling date: 13 Sep 2021 Issue date: 24 Mar 2022 |
Grant Filling date: 6 Sep 2019 Issue date: 1 Mar 2022 |
Application Filling date: 16 Sep 2019 Issue date: 17 Feb 2022 |
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement
Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching
Sutro BioPharma: Good Stewardship Through Early Trials
Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting
ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity
Sutro Biopharma: Partnership Progress Warrants Exposure
Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal
-
What's the price of Sutro Biopharma stock today?
One share of Sutro Biopharma stock can currently be purchased for approximately $0.86.
-
When is Sutro Biopharma's next earnings date?
Unfortunately, Sutro Biopharma's (STRO) next earnings date is currently unknown.
-
Does Sutro Biopharma pay dividends?
No, Sutro Biopharma does not pay dividends.
-
How much money does Sutro Biopharma make?
Sutro Biopharma has a market capitalization of 153.78M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 126.84% to 153.73M US dollars. Sutro Biopharma made a loss 106.79M US dollars in net income (profit) last year or -$0.68 on an earnings per share basis.
-
What is Sutro Biopharma's stock symbol?
Sutro Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "STRO".
-
What is Sutro Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sutro Biopharma?
Shares of Sutro Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sutro Biopharma's key executives?
Sutro Biopharma's management team includes the following people:
- Mr. William J. Newell Chief Executive Officer & Director(age: 67, pay: $893,050)
- Dr. Trevor J. Hallam Pres of Research & Chief Scientific Officer(age: 66, pay: $760,530)
- Ms. Linda A. Fitzpatrick Chief People & Communications Officer(age: 68, pay: $595,790)
-
How many employees does Sutro Biopharma have?
As Jul 2024, Sutro Biopharma employs 300 workers, which is 1% less then previous quarter.
-
When Sutro Biopharma went public?
Sutro Biopharma, Inc. is publicly traded company for more then 6 years since IPO on 27 Sep 2018.
-
What is Sutro Biopharma's official website?
The official website for Sutro Biopharma is sutrobio.com.
-
Where are Sutro Biopharma's headquarters?
Sutro Biopharma is headquartered at 111 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Sutro Biopharma?
Sutro Biopharma's mailing address is 111 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 08816500.
-
What is Sutro Biopharma stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Sutro Biopharma in the last 12 months, the avarage price target is $13. The average price target represents a 1409.87% change from the last price of $0.86.
Sutro Biopharma company profile:
Sutro Biopharma, Inc.
sutrobio.comExchange:
NASDAQ
Full time employees:
302
Industry:
Biotechnology
Sector:
Healthcare
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
111 Oyster Point Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001382101
ISIN: US8693671021
CUSIP: 869367102
